These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

96 related articles for article (PubMed ID: 2561387)

  • 1. [Low molecular weight heparins].
    Doutremepuich C; Lalanne MC; Guyot M; Doutremepuich F; Fernandez G; De Seze O; Deharo E; Vairel EG; Quilichini R
    Ann Pharm Fr; 1989; 47(3):109-16. PubMed ID: 2561387
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Low molecular weight heparins in everyday practice].
    Horellou MH; Samama M
    J Mal Vasc; 1991; 16(2):179-83. PubMed ID: 1650391
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Overview of low molecular weight heparins and heparinoids: basic and clinical aspects.
    Hirsh J
    Aust N Z J Med; 1992 Oct; 22(5):487-95. PubMed ID: 1280097
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Low molecular weight heparins].
    Kher A; Bara L; Samama M
    Pathol Biol (Paris); 1986 Jan; 34(1):61-9. PubMed ID: 3517772
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Low molecular weight heparin: a critical analysis of clinical trials.
    Green D; Hirsh J; Heit J; Prins M; Davidson B; Lensing AW
    Pharmacol Rev; 1994 Mar; 46(1):89-109. PubMed ID: 8190751
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Low molecular weight heparins--state-of-the-art and unsolved issues.
    Breddin HK
    Blood Coagul Fibrinolysis; 1993 Dec; 4 Suppl 1():S17-9. PubMed ID: 8180324
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ex-vivo and in-vitro evidence that low molecular weight heparins exhibit less binding to plasma proteins than unfractionated heparin.
    Young E; Wells P; Holloway S; Weitz J; Hirsh J
    Thromb Haemost; 1994 Mar; 71(3):300-4. PubMed ID: 8029793
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Low-molecular weight heparins in post-surgical recovery].
    Doutremepuich C; Anne MC; Fernandez G; Pereira F; de Seze O; Doutremepuich F
    Ann Biol Clin (Paris); 1988; 46(3):190-4. PubMed ID: 2841894
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Are all low molecular weight heparins equivalent in the management of venous thromboembolism?
    Fareed J; Jeske W; Fareed D; Clark M; Wahi R; Adiguzel C; Hoppensteadt D
    Clin Appl Thromb Hemost; 2008 Oct; 14(4):385-92. PubMed ID: 18815137
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Low molecular weight heparin for the out-of-hospital treatment of venous thrombosis: rationale and clinical results.
    Hirsh J; Crowther M
    Thromb Haemost; 1997 Jul; 78(1):689-92. PubMed ID: 9198240
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Current indications of low-molecular-weight heparins].
    Vignes S; Meyer G; Marjanovic Z; Farge-Bancel D
    Ann Med Interne (Paris); 1997; 148(2):154-62. PubMed ID: 9238441
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Management of venous thromboembolic disease. The impact of low-molecular-weight heparin.
    Tapson VF; Hull RD
    Clin Chest Med; 1995 Jun; 16(2):281-94. PubMed ID: 7656540
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Low-molecular-weight heparin in the treatment of deep venous thrombosis.
    Hauer KE
    West J Med; 1998 Oct; 169(4):240-4. PubMed ID: 9795594
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [State of the art: low-molecular-weight heparin and beyond].
    Cimminiello C; Casali G; Vitali L
    Minerva Cardioangiol; 2000 Dec; 48(12 Suppl 1):61-5. PubMed ID: 11253343
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Product individuality of commercially available low-molecular-weight heparins and their generic versions: therapeutic implications.
    Maddineni J; Walenga JM; Jeske WP; Hoppensteadt DA; Fareed J; Wahi R; Bick RL
    Clin Appl Thromb Hemost; 2006 Jul; 12(3):267-76. PubMed ID: 16959680
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Differentiating low-molecular-weight heparins based on chemical, biological, and pharmacologic properties: implications for the development of generic versions of low-molecular-weight heparins.
    Jeske WP; Walenga JM; Hoppensteadt DA; Vandenberg C; Brubaker A; Adiguzel C; Bakhos M; Fareed J
    Semin Thromb Hemost; 2008 Feb; 34(1):74-85. PubMed ID: 18393144
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [How to standardize low molecular weight heparins].
    Doutremepuich C; Puyal C; Lalanne MC; Doutremepuich F; De Sèze O
    Ann Biol Clin (Paris); 1990; 48(4):221-5. PubMed ID: 2163227
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Perspectives on antithrombotic agents: from unfractionated heparin to new antithrombotics.
    Agnelli G; Sonaglia F
    Haematologica; 2002 Jul; 87(7):757-70. PubMed ID: 12091128
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Low- and ultra-low-molecular-weight heparins.
    Kakkar AK
    Best Pract Res Clin Haematol; 2004 Mar; 17(1):77-87. PubMed ID: 15171959
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Low molecular weight heparins prevent thrombin-induced thrombo-embolism in mice despite low anti-thrombin activity. Evidence that the inhibition of feed-back activation of thrombin generation confers safety advantages over direct thrombin inhibition.
    Momi S; Nasimi M; Colucci M; Nenci GG; Gresele P
    Haematologica; 2001 Mar; 86(3):297-302. PubMed ID: 11255277
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.